The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Nektar Therapeutics

  • NKTR
  • NASDAQ
  • Consumer Products
  • Latest 10.88
  • Currency US$
  • Change 0.30
  • Percent Change 2.836 %
  • Volume 1,735,062
  • Tue Apr 15, 2014 04:00 PM EDT NASDAQ data delayed 15 minutes.
  • Open 10.63
  • Previous Close 10.58
  • High 10.91
  • Low 10.10
  • Bidx1 9.50
  • Askx1 19.93
  • 52-week High03/04 15.34
  • 52-week Low06/05 8.72
  • Beta 1.514
  • Market Cap 1,263.28M
  • EPS -1.40
  • P/E
  • Forward P/E
  • PEG
  • Annual Dividend 0.0000
  • Yield

News

Financials & Calendars

Income Statement

  • Sales $148,920,000
  • Earnings $-162,550,000
  • Return on Equity n/a

Cash Flow

  • Cash Flow --
  • Cash $39,060,000
  • Current Ratio 2.63

12 months ended Dec 31, 2013.

Trailing 12 month results shown above.
All data is in U.S. dollars.

Balance Sheet

  • Assets $434,520,000
  • Liabilities $524,430,000
  • Liabilities-to-Equity Ratio n/a

Price Ratios

  • Price to Sales 8.48
  • Price to Book n/a
  • Price to Cash Flow n/a

Event Calendar

Event Last   Next  
Earnings Feb 26 $-0.16 May 8 $0.06
Surprises Feb 26 156.25% n/a n/a
Dividends n/a n/a n/a n/a
Splits n/a -- n/a n/a

12 months ended Apr 16, 2014.

A look at major corporate events and financial announcements that are coming up.

Company Information

About the Company

Nektar Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are designed to meet unmet medical needs and improve the benefits of drugs for patients. Its product pipeline consists of drug candidates across a number of therapeutic areas, including oncology, pain. In the area of pain, Nektar has a worldwide license agreement with AstraZeneca for NKTR-118, an investigational drug candidate, being evaluated in Phase 3 clinical studies as a once-daily, oral tablet for the treatment of opioid-induced constipation. The agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of NKTR-118 and an opioid. Also in the area of pain, NKTR-181, the company's wholly-owned novel mu-opioid analgesic molecule, is being evaluated in Phase 1 clinical studies. Nektar Therapeutics is headquartered in San Francisco, California.

Related Securities
Symbol Type Latest % Chg

Officers

  • Robert B. Chess Chairman of the Board of Direc
  • Howard W. Robin Chief Executive Officer; Presi
  • Company Type: n/a
  • Company Status: n/a
  • Full-time Employees: n/a
  • Incorporation: United States,
    n/a
  • Top 1000 Ranking: Profit: n/a
    Revenue: n/a
    Assets: n/a

Head Office

455 MISSION BAY BOULEVARD SOUT
SAN FRANCISCO, CA
94158

Phone: (415)-482-5300
Fax: (415)-3395300

investors@nektar.com
www.nektar.com

Ideas & Discussion

Live Discussion of NKTR on StockTwits